Inotuzumab ozogamicin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Inotuzumab ozogamicin" in English language version.

refsWebsite

Global rank English rank

6doi.org

2^nd place

5nih.gov

4^th place

3fda.gov

447^th place

338^th place

2web.archive.org

1^st place

1hres.ca

low place

1canada.ca

1,712^th place

1,063^rd place

1medicines.org.uk

3,823^rd place

2,387^th place

1semanticscholar.org

11^th place

8^th place

1adcreview.com

low place

1who.int

195^th place

302^nd place

1informa.com

low place

1theguardian.com

12^th place

11^th place

1nytimes.com

7^th place

1businesswire.com

615^th place

407^th place

adcreview.com

"Inotuzumab ozogamicin (CMC-544)". ADC Review. 20 February 2016.

businesswire.com

pfizer.newshq.businesswire.com

"Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility. May 2013". Archived from the original on 8 August 2014. Retrieved 20 July 2014.

canada.ca

"Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.

doi.org

Ricart AD (October 2011). "Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin". Clinical Cancer Research. 17 (20): 6417–6427. doi:10.1158/1078-0432.ccr-11-0486. PMID 22003069.
Yang X (13 May 2020). "Inotuzumab Ozogamicin is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High- Risk Molecular Features, Including Tp53 Loss". doi:10.26226/morressier.5ebc261fffea6f735881a254. S2CID 242875059. Retrieved 21 August 2023.
Damle NK, Frost P (August 2003). "Antibody-targeted chemotherapy with immunoconjugates of calicheamicin". Current Opinion in Pharmacology. 3 (4): 386–390. doi:10.1016/S1471-4892(03)00083-3. PMID 12901947.
Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. (2002). "Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia". Bioconjugate Chemistry. 13 (1): 47–58. doi:10.1021/bc010021y. PMID 11792178.
DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, et al. (March 2004). "Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies". Blood. 103 (5): 1807–1814. doi:10.1182/blood-2003-07-2466. PMID 14615373.

dx.doi.org

Yang X (13 May 2020). "Inotuzumab Ozogamicin is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High- Risk Molecular Features, Including Tp53 Loss". doi:10.26226/morressier.5ebc261fffea6f735881a254. S2CID 242875059. Retrieved 21 August 2023.

fda.gov

New Drug Therapy Approvals 2017 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2018. Retrieved 16 September 2020.
"FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia". U.S. Food and Drug Administration. 6 March 2024. Retrieved 9 March 2024. This article incorporates text from this source, which is in the public domain.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

hres.ca

hpr-rps.hres.ca

"Regulatory Decision Summary for Besponsa". 23 October 2014.

informa.com

drugprofiles.informa.com

"Inotuzumab Ozogamicin". Informa Biomedtracker. Archived from the original on 19 August 2017. Retrieved 19 August 2017.

medicines.org.uk

"Besponsa 1 mg powder for concentrate for solution for infusion". UK Electronic Medicines Compendium. June 2017. Retrieved 19 August 2017.

nih.gov

pubmed.ncbi.nlm.nih.gov

Ricart AD (October 2011). "Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin". Clinical Cancer Research. 17 (20): 6417–6427. doi:10.1158/1078-0432.ccr-11-0486. PMID 22003069.
Damle NK, Frost P (August 2003). "Antibody-targeted chemotherapy with immunoconjugates of calicheamicin". Current Opinion in Pharmacology. 3 (4): 386–390. doi:10.1016/S1471-4892(03)00083-3. PMID 12901947.
Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. (2002). "Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia". Bioconjugate Chemistry. 13 (1): 47–58. doi:10.1021/bc010021y. PMID 11792178.
DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, et al. (March 2004). "Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies". Blood. 103 (5): 1807–1814. doi:10.1182/blood-2003-07-2466. PMID 14615373.

dailymed.nlm.nih.gov

"Besponsa- inotuzumab ozogamicin injection, powder, lyophilized, for solution". DailyMed. 15 September 2020. Retrieved 16 November 2020.

nytimes.com

Sorkin AR, Wilson D (25 January 2009). "Pfizer Agrees to Pay $68 Billion for Rival Drug Maker Wyeth". The New York Times.

semanticscholar.org

api.semanticscholar.org

Yang X (13 May 2020). "Inotuzumab Ozogamicin is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High- Risk Molecular Features, Including Tp53 Loss". doi:10.26226/morressier.5ebc261fffea6f735881a254. S2CID 242875059. Retrieved 21 August 2023.

theguardian.com

"Celltech sold to Belgian firm in £1.5bn deal". The Guardian. 18 May 2004.

web.archive.org

"Inotuzumab Ozogamicin". Informa Biomedtracker. Archived from the original on 19 August 2017. Retrieved 19 August 2017.
"Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility. May 2013". Archived from the original on 8 August 2014. Retrieved 20 July 2014.

who.int

"Recommended INN: List 54" (PDF). WHO Drug Information. 19 (3). 2005.